Related Experiment Video
Updated: May 28, 2025

Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
ACOT12, a novel factor in the pathogenesis of kidney fibrosis, modulates ACBD5
Ee Hyun Kim1,2, Mi Kyung Kim3, MiSun Choe4
1Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, South Korea.
Abstract:
Lipid metabolism, particularly fatty acid oxidation dysfunction, is a major driver of renal fibrosis. However, the detailed regulatory mechanisms underlying this process remain unclear. Here we demonstrated that acyl-CoA thioesterase 12 (Acot12), an enzyme involved in the hydrolysis of acyl-CoA thioesters into free fatty acids and CoA, is a key regulator of lipid metabolism in fibrotic kidneys. A significantly decreased level of ACOT12 was observed in kidney samples from human patients with chronic kidney disease as well as in samples from mice with kidney injuries. Acot12 deficiency induces lipid accumulation and fibrosis in mice subjected to unilateral ureteral obstruction (UUO). Fenofibrate administration does not reduce renal fibrosis in Acot12-/- mice with UUO. Moreover, the restoration of peroxisome proliferator-activated receptor α (PPARα) in Acot12-/-Pparα-/- kidneys with UUO exacerbated lipid accumulation and renal fibrosis, whereas the restoration of Acot12 in Acot12-/- Pparα-/- kidneys with UUO significantly reduced lipid accumulation and renal fibrosis, suggesting that, mechanistically, Acot12 deficiency exacerbates renal fibrosis independently of PPARα. In Acot12-/- kidneys with UUO, a reduction in the selective autophagic degradation of peroxisomes and pexophagy with a decreased level of ACBD5 was observed. In conclusion, our study demonstrates the functional role and mechanistic details of Acot12 in the progression of renal fibrosis, provides a preclinical rationale for regulating Acot12 expression and presents a novel means of preventing renal fibrosis.
Insights
Acyl-CoA thioesterase 12 (Acot12) deficiency drives kidney fibrosis by disrupting lipid metabolism and pexophagy. Restoring Acot12 reduces fibrosis, offering a new therapeutic target for kidney disease.
Area of Science:
- Nephrology
- Molecular Biology
- Biochemistry
Background:
- Lipid metabolism dysfunction, especially impaired fatty acid oxidation, is a key factor in renal fibrosis.
- The precise regulatory mechanisms governing lipid metabolism in fibrotic kidneys are not fully understood.
Purpose of the Study:
- To investigate the role of acyl-CoA thioesterase 12 (Acot12) in regulating lipid metabolism and its impact on renal fibrosis progression.
- To elucidate the mechanistic link between Acot12, lipid accumulation, and kidney fibrosis.
Main Methods:
- Analysis of Acot12 levels in human chronic kidney disease and mouse kidney injury samples.
- Utilizing Acot12-deficient (Acot12-/-) and double-knockout (Acot12-/-Pparα-/-) mouse models subjected to unilateral ureteral obstruction (UUO).
- Assessing lipid accumulation, fibrosis, and pexophagy markers (ACBD5).
Main Results:
- Significantly decreased Acot12 levels were found in human and mouse fibrotic kidneys.
- Acot12 deficiency exacerbated lipid accumulation and renal fibrosis in UUO mice.
- Acot12's role in fibrosis progression was independent of peroxisome proliferator-activated receptor α (PPARα).
- Acot12 deficiency led to reduced pexophagy and lower ACBD5 levels in fibrotic kidneys.
Conclusions:
- Acot12 is a critical regulator of lipid metabolism and plays a protective role against renal fibrosis.
- Acot12 deficiency promotes renal fibrosis through impaired lipid metabolism and reduced pexophagy, independent of PPARα.
- Targeting Acot12 presents a novel therapeutic strategy for preventing and treating kidney fibrosis.

